On January 6, 2021, Werewolf Therapeutics, Inc. closed the transaction. The transaction was led by new investor RA Capital Management, L.P. The transaction included participation from 18 investors and also includes new investors RA Capital Management, L.P., Deerfield Management Company, L.P., HBM Healthcare Investments AG (SWX:HBMN), a fund managed by HBM Partners Ltd., Soleus Capital, Adage Capital Management, L.P., Sphera Healthcare Us Inc., CaaS Capital Management LP, and existing investors MPM Capital, Longwood Fund, Taiho Ventures, LLC, Arkin Bio Venture Partners Ltd., UPMC Enterprises, DC Investment Partners. As a part of funding, Derek DiRocco of RA Capital Management, L.P. and Elise Wang of Deerfield Management Company, L.P. joined the board of the company.